SCHEMBL4389976

SCHEMBL4389976

Cc1cc(NCc2ccc(F)cc2)cc(=O)n1Cc1ccc(F)cc1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 7/20 0.57
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
HSD17B10 Q99714 1/20 0.48
GRIA2 P42262 1/20 0.47
KMT2A Q03164 3/20 0.47
THRB P10828 1/20 0.43
TYMS P04818 1/20 0.43
PPARA Q07869 1/20 0.42
MEN1 O00255 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
CES2 O00748 1/20 0.41
BRD4 O60885 1/20 0.40
KAT2B Q92831 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4382529 0.79 ADRA2B (0.43) ADRA2AGRIA2KMT2AMEN1
SCHEMBL4382245 0.75 KDM4E (0.51) KDM4EALDH1A1HSD17B10THRBTYMS
SCHEMBL4764015 0.69 KMT2A (0.69) KDM4EALDH1A1HSD17B10KMT2AMEN1
SCHEMBL24630265 0.68 ADRA2A (0.65) ADRA2AKDM4EALDH1A1KMT2AMEN1
SCHEMBL21333131 0.68 ALDH1A1 (0.59) KDM4EALDH1A1HSD17B10KMT2ATHRB
SCHEMBL6419238 0.67 LMNA (0.61) KDM4EALDH1A1HSD17B10KMT2ATHRB
SCHEMBL10055033 0.67 LMNA (0.61) KDM4EALDH1A1HSD17B10KMT2ATHRB
SCHEMBL21667283 0.67 KMT2A (0.50) ALDH1A1HSD17B10KMT2AMEN1SMN1; SMN2
SCHEMBL171854 0.67 MAPT (0.67) KDM4EALDH1A1HSD17B10KMT2ATHRB
SCHEMBL6414545 0.67 MAPT (0.67) KDM4EALDH1A1HSD17B10KMT2ATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
EP-1490064-B1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE PHARMACIA CORP (US) 2009-11-18 EP disclosed
US-7067540-B2 Substituted pyridinones PHARMACIA CORPORATION (US) 2006-06-27 US disclosed
US-20050176775-A1 Substituted pyridinones PHARMACIA CORPORATION 2005-08-11 US disclosed
WO-2005018557-A2 SUBSTITUTED PYRIDINONES PHARMACIA CORPORATION (US) 2005-03-03 WO disclosed
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058964-A1 Substituted pyridinones MAPK1, MAPK6, MAPK7 ADRA2A 722/4885KDM4E 3869/4885ALDH1A1 787/4885
US-20050176775-A1 Substituted pyridinones MAPK1, MAPK6, MAP3K6 ADRA2A 562/4885KDM4E 3921/4885ALDH1A1 741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.